Agios Pharmaceuticals Inc. AGIO stock is trading lower after the update on the sickle cell disease program. The company ...

This deals another blow to tebapivat’s development prospects following its May 2026 termination in MDS due to efficacy ...

Agios Pharmaceuticals AGIO announced that it has discontinued the development of its investigational drug, tebapivat, for the ...

The biotech firm said it will discontinue development of its therapy for sickle cell disease following the outcome of a Phase ...

Agios Pharmaceuticals shares rose Tuesday after the U.S. Food and Drug Administration granted priority review to the company's supplemental new drug application for mitapivat to treat sickle cell ...

Proliferating cells, in particular tumor cells, express a dimeric isoenzyme of pyruvate kinase, termed Tumor M2 pyruvate kinase. In the last few years, much attention has been paid to this novel tumor ...

– In Adults with Pyruvate Kinase (PK) Deficiency Who Are Not Regularly Transfused, PYRUKYND® Significantly Increased Hemoglobin Level, Decreased Hemolysis and Improved Patient-Reported Outcomes – – ...

Pyruvate kinase M2 (PKM2) occupies a central role in cancer metabolism, catalysing the final and rate-limiting step of glycolysis by converting phosphoenolpyruvate to pyruvate. It exists in ...

The FDA has approved Pyrukynd (mitapivat) for the treatment of hemolytic anemia in adults with pyruvate kinase deficiency. The Food and Drug Administration (FDA) has approved Pyrukynd ® (mitapivat) ...

(RTTNews) - Agios Pharmaceuticals Inc. (AGIO), said on Friday that the FDA has approved Pyrukynd for the treatment of hemolytic anemia in adults with pyruvate kinase or PK deficiency, a rare, ...